Insider Trading November 20, 2026 08:01 PM

Glaukos CFO Alex Thurman Offloads $3.55 Million in Stock, Exercises Options

The sale, executed under a pre-arranged 10b5-1 plan, comes as shares trade near a 52-week high following a 138% rally over the past year.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
GKOS

Glaukos Corp (NASDAQ:GKOS) Senior Vice President and Chief Financial Officer Alex R. Thurman sold 14,800 shares of common stock on November 18, 2026, for total proceeds of $3,553,763, at prices between $232.18 and $246.41 per share. The transaction occurred under a Rule 10b5-1 trading plan adopted on August 18, 2026, which also covered the exercise of options set to expire on March 15, 2027. On the same day, Thurman exercised 15,000 stock options at $45.71 per share, totaling $685,650. Following these moves, his direct beneficial ownership stands at 43,906 shares, including 5,230 unvested restricted stock units. The sales coincide with the stock trading near its 52-week high of $255.19, after a 138% return over the past year, though some analyses suggest the shares may be overvalued. Meanwhile, Glaukos reported strong third-quarter 2026 revenue of $211 million, up 58% year-over-year, and raised its 2026 revenue guidance by 13%, with a 2027 outlook of approximately $1 billion. Several analysts have responded by raising their price targets.

Glaukos CFO Alex Thurman Offloads $3.55 Million in Stock, Exercises Options
GKOS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Glaukos CFO Alex Thurman sold 14,800 shares for $3.55 million under a Rule 10b5-1 plan adopted in August 2026, while also exercising 15,000 options at $45.71 per share.
  • The transactions occurred near the stock's 52-week high of $255.19, following a 138% gain over the past year, though some analyses flag potential overvaluation.
  • Glaukos reported strong Q3 2026 revenue of $211 million, up 58% year-over-year, and raised 2026 guidance by 13% with a 2027 outlook of approximately $1 billion, prompting multiple analyst price target increases.
  • The healthcare sector, particularly medical devices and ophthalmic equipment, is impacted by these developments, as they reflect insider confidence and company performance.

Alex R. Thurman, Senior Vice President and Chief Financial Officer of Glaukos Corp (NASDAQ:GKOS), sold 14,800 shares of common stock on November 18, 2026, generating total proceeds of $3,553,763. The shares changed hands at prices ranging from $232.18 to $246.41 apiece. The transaction took place as the stock hovered near its 52-week high of $255.19, following a striking 138% return over the past year. Nonetheless, some analytical assessments indicate the stock may be overvalued at current levels.

The sale was conducted pursuant to a Rule 10b5-1 trading plan that Thurman adopted on August 18, 2026. This pre-arranged plan also governed the exercise of options scheduled to expire on March 15, 2027. On the same date, Thurman acquired 15,000 shares of common stock by exercising stock options at an exercise price of $45.71 per share, for a total cost of $685,650. That option exercise was likewise part of the pre-arranged Rule 10b5-1 plan.

After these transactions, Thurman's direct beneficial ownership in Glaukos Corp amounts to 43,906 shares of common stock. This figure includes 5,230 restricted stock units that have not yet vested or been delivered to him.

The company's outlook appears positive, with analyst sentiment reflecting upward revisions. According to available data, 11 analysts have revised their earnings estimates upward for the upcoming period. Additional detailed analysis and further proprietary insights are accessible through subscription platforms.

In other recent developments, Glaukos Corporation reported significant financial achievements for the third quarter of 2026. Total revenue reached $211 million, representing a 58% increase year-over-year and surpassing expectations from analysts at firms such as Piper Sandler and Needham. The revenue performance was highlighted by the strength of the company's Epioxa segment, which contributed to a positive turn in profitability. Glaukos management also raised its revenue guidance for 2026 by 13% and introduced a 2027 revenue outlook of approximately $1 billion, exceeding previous consensus estimates.

Several analyst firms have responded to these developments by raising their stock price targets for Glaukos. BTIG increased its target to $252, while H.C. Wainwright set theirs at $248, citing the strong third-quarter results. Piper Sandler and Needham also raised their targets to $240 and $251, respectively, both maintaining positive ratings on the stock. Mizuho, noting impressive U.S. Glaucoma and Corneal Health performance, raised its price target to $225. These updates reflect the analysts' positive outlook on Glaukos following its robust financial results.

The stock most recently closed at $237.31, down $0.79 or 0.33%, on volume of 15:59:59. In after-hours trading, the price remained unchanged at $237.31.

Risks

  • Insider sales, even under pre-arranged plans, can be interpreted by some investors as a signal of reduced confidence, potentially pressuring the stock price in the healthcare equipment sector.
  • Analyst assessments suggest the stock may be overvalued at current levels, which could lead to a correction if growth expectations are not met, affecting the medical devices market.
  • The company's future performance depends on the continued strength of its Epioxa segment and the achievement of its raised guidance, with risks of execution shortfalls impacting the broader ophthalmic device industry.

More from Insider Trading

WEX COO Offloads $149,835 in Stock as Shares Trade Near $175 Nov 20, 2026 BETA Technologies CEO Offloads $855,016 in Stock as Shares Slide 27% Nov 20, 2026 Lindblad Director Offloads $6.4M in Stock Under Pre-Set Plan Nov 20, 2026 Ethos Technologies President Wang Lingke Offloads $3.8 Million in LIFE Stock Under Prearranged Plan Nov 20, 2026 Ethos Technologies CEO Offloads $2.92 Million in Shares Under 10b5-1 Plan Nov 20, 2026